APLT vs. KALV, YMAB, VERV, AVTE, ATXS, ABUS, IGMS, TVTX, ALT, and LRMR
Should you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include KalVista Pharmaceuticals (KALV), Y-mAbs Therapeutics (YMAB), Verve Therapeutics (VERV), Aerovate Therapeutics (AVTE), Astria Therapeutics (ATXS), Arbutus Biopharma (ABUS), IGM Biosciences (IGMS), Travere Therapeutics (TVTX), Altimmune (ALT), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical preparations" industry.
Applied Therapeutics (NASDAQ:APLT) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership, community ranking and media sentiment.
KalVista Pharmaceuticals has lower revenue, but higher earnings than Applied Therapeutics. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Applied Therapeutics had 5 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 8 mentions for Applied Therapeutics and 3 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.62 beat Applied Therapeutics' score of 0.17 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.
Applied Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 150.57%. KalVista Pharmaceuticals has a consensus price target of $25.00, indicating a potential upside of 109.73%. Given Applied Therapeutics' higher possible upside, research analysts plainly believe Applied Therapeutics is more favorable than KalVista Pharmaceuticals.
Applied Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
98.3% of Applied Therapeutics shares are held by institutional investors. 8.6% of Applied Therapeutics shares are held by company insiders. Comparatively, 12.3% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
KalVista Pharmaceuticals received 258 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 73.93% of users gave KalVista Pharmaceuticals an outperform vote while only 56.35% of users gave Applied Therapeutics an outperform vote.
KalVista Pharmaceuticals' return on equity of -86.06% beat Applied Therapeutics' return on equity.
Summary
Applied Therapeutics beats KalVista Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Applied Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied Therapeutics Competitors List
Related Companies and Tools
